A biomarker is a measurable indicator of the severity or presence of a specific disease state. It indicates a change in expression or state of a biomolecule, that correlates with the risk or progression of a disease, or with the susceptibility of the disease to a given treatment. Biomarkers are applied in a number of ways, including measuring the progress of disease, evaluating the most effective therapeutic regimes for a particular disease, and establishing long-term susceptibility to a disease or its recurrence.
Intomics track record:
Intomics has been involved in several biomarker discovery projects where expression data, genomics information, protein networks, and literature mining were combined to identify novel biomarkers. In follow-up validation experiments in model systems these biomarkers have shown validation rates exceeding 90 %.
The value to our customers:
Identifying the right biomarker(s) for a disease or disease state is a very important step in managing healthcare in an efficient and cost-effective way. Optimized biomarkers can enable much more targeted use of drugs and better patient stratification for clinical trials.
What we do:
In a standard Biomarker Discovery project, we combine patient data (typically case-control data) with in-depth data mining and understanding of protein pathways and networks to investigate and identify novel drug targets. The text mining includes our proprietary inBio Know™ data mining platform and for protein-protein interaction networks we apply our proprietary PPI network database, inBio Map™.
We work closely with our clients in the planning of each project. Each project is tailored specifically to generate the most valuable outcome, taking available data, in-house capabilities, timelines etc. into account.
The duration of Biomarker Identification projects is usually from 4 to 12 months, depending on the complexity of the project.
Close project cooperation and communication:
A key factor in the successful outcomes with our partners, is the close interaction and communication we have from planning the projects and all the way through project execution and presentation of the project deliverables. We typically have bi-weekly Webex update/planning meetings with the client and have face-to-face meetings every 2-3 months during the project. At the end of the project, we present the project deliverables and conclusions in a face-to-face meeting. All face-to-face meetings take place at our clients’ facility, unless another location is desired.
In our comprehensive project report, we deliver a prioritized list of biomarkers, or multi-marker signatures, with evidence-based documentation for each of these. Apart from the biomarker/signature list, the report also documents the project steps and details key project findings. Additionally, we present potential next steps in the project for discussion, if relevant.
What we do
Drug target identification
Helping clients identify genes/proteins as target candidates with remarkable results.
Helping clients uncover clinical relevant biomarkers in complex diseases enabling precise patient stratification.
Helping clients in investigating the potential of repositioning marketed drugs into other disease areas.
Helping clients decide on the correct model test platform for optimal drug development results.
Helping clients build and evolve their inhouse bioinformatic capabilities with expert counseling.